




Atty. Do No. 31386A 070165.0593
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Coller *et al.*
Serial No. : 09/855,886 Examiner: Helms, L.
Filed : May 15, 2001 Group Art Unit: 1642
For : METHOD OF INHIBITING ANGIOGENESIS AND
TUMOR GROWTH AND PREVENTING TUMOR
GROWTH AND METASTASES

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

I hereby certify that this paper is being deposited on July 7, 2003 with
the United States Postal Service as first class mail in an envelop addressed to:
Assistant Commissioner for Patents, Alexandria, VA 22313-1450

Lisa B. Kole
Attorney Name

Signature

35,225
PTO Registration No.

July 7, 2003
Date of Signature

Assistant Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In supplement to the Information Disclosure Statement filed on July 10, 2002, and pursuant to the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants respectfully request that the publications relating to the above-mentioned application listed herein in reverse chronological order and on the accompanying PTO Form 1449 be considered by the Examiner and made of record in the U.S. Patent and Trademark Office.

Numbering of the cited references begins with the number "62", to distinguish over the sixty-one references cited in the earlier submitted Information Disclosure Statement.

07/11/2003 MBLANCO 00000017 09055886

02 FC:1806

180.00 DP

NY02:448147.1

12
KD
86-03

62. Trikha et al., "Multiple Roles for Platelet GPIIb/IIIa and $\alpha_v\beta_3$ Integrins in Tumor Growth, Angiogenesis, and Metastasis," *Cancer Res.* 2002; 62:2824-2833.
63. Trikha et al., ""Platelets and Cancer: Implications for Antiangiogenic Therapy," *Seminars in Thrombosis and Hemostasis* 2002; 28:39-44.
64. Cohen et al., "Potential Future Clinical Applications for the GPIIb/IIIa Antagonist, Abciximab in Thrombosis, Vascular and Oncological Indications," *Pathol. Oncol. Res.* 2000; 6(3):163-174.
65. Coller, "Potential non-glycoprotein IIb/IIIa effects of abciximab," *Am. Heart J.* 1999; 138:S1-S5.
66. Luna et al., "Antagonists of integrin alpha v beta 3 inhibit retinal neovascularization in a murine model." *Lab. Invest.* 1996; 75:563-573.

Copies of references 62-65 are enclosed. A copy of the abstract of reference 66 is enclosed; a copy of the complete reference will follow.

The submission of this Supplemental Information Disclosure Statement does not represent that a search has been made or that no better art exists, and does not constitute an admission that any of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Applicants believe that a fee of \$180.00 is required for this submission, and submits said fee herewith. In the event that any additional fee is required, the Commissioner is hereby authorized to charge any fees or credit any overpayment to Deposit Account No. 02-4377. Two copies of this paper are enclosed.

Respectfully submitted,

BAKER BOTTS D.L.F.

A handwritten signature in cursive script, appearing to read 'Lisa B. Kole', written over a horizontal line.

Lisa B. Kole

Patent Office Reg. No. 35,255

Attorney for Applicants